Glycoconjugate vaccines containing peptidoglycan
AssigneeNabi Biopharmaceuticals
InventorsAli Fattom, Ed Hausknecht, Scott Winston, Steve Fuller
Life of this patent
Estimating the term…
Abstract
The present invention relates to vaccines for treating bacterial infections, which vaccines comprise a glycoconjugate immunogen comprising at least one capsular polysaccharide conjugated to a carrier protein, such that the capsular polysaccharide contains an amount of peptidoglycan effective to improve the vaccine's properties.
Claims18
A vaccine, comprising:
- (A) a therapeutically effective amount of a glycoconjugate immunogen comprising at least one capsular polysaccharide and a carrier protein, wherein said capsular polysaccharide comprises at least about 5% (w/w) peptidoglycan, based on the weight of the capsular polysaccharide, and
- (B) a pharmaceutically acceptable carrier for said immunogen.
A method for making a vaccine comprising a glycoconjugate immunogen comprised of at least one capsular polysaccharide and a carrier protein, comprising:
- (A) conjugating at least one capsular polysaccharide to a carrier protein to form a glycoconjugate immunogen, wherein the capsular polysaccharide comprises at least about 5% (w/w) peptidoglycan, based on the weight of the capsular polysaccharide and
- (B) formulating a therapeutically effective amount of the glycoconjugate immunogen with a pharmaceutically acceptable carrier for said immunogen.
A method for enhancing the conjugation efficiency of a capsular polysaccharide to a carrier protein, comprising (i) selecting capsular polysaccharide that comprises an amount of peptidoglycan effective to contribute to enhanced conjugation efficiency of the capsular polysaccharide and carrier protein, and (ii) conjugating the capsular polysaccharide to a carrier protein.
A method for enhancing the immunogenicity of a vaccine, comprising (i) selecting capsular polysaccharide comprises an amount of peptidoglycan that contributes to enhanced immunogenicity of the vaccine, (ii) conjugating the capsular polysaccharide with a carrier protein to form a glycoconjugate immunogen and (iii) preparing a vaccine comprising the glycoconjugate immunogen and a pharmaceutically acceptable carrier.
A vaccine, comprising:
- (A) a therapeutically effective amount of a glycoconjugate immunogen comprising at least one capsular polysaccharide and a carrier protein, wherein said capsular polysaccharide comprises an amount of peptidoglycan effective to increase the conjugation efficiency of the capsular polysaccharide to the carrier protein by at least about 20% relative to capsular polysaccharide comprising about 2% peptidoglycan, and
- (B) a pharmaceutically acceptable carrier for said immunogen.
Dependencies are inferred from the claim text.